0001479290-20-000038.txt : 20200224 0001479290-20-000038.hdr.sgml : 20200224 20200224160849 ACCESSION NUMBER: 0001479290-20-000038 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20200224 ITEM INFORMATION: Results of Operations and Financial Condition FILED AS OF DATE: 20200224 DATE AS OF CHANGE: 20200224 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 20644368 BUSINESS ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: 510-742-3400 MAIL ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 8-K 1 rvncq419er8-k.htm 8-K Document
false0001479290 0001479290 2020-02-24 2020-02-24
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
 
 
 
 
FORM 8-K
 
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 24, 2020
 
 
 
Revance Therapeutics, Inc.
 
(Exact name of registrant as specified in its charter)
 
 
 
 
Delaware
001-36297
77-0551645
(State or other jurisdiction of incorporation)
(Commission File No.)
(I.R.S. Employer Identification No.)
7555 Gateway Boulevard, Newark, California, 94560
(Address, including zip code, of principal executive offices)

(510) 742-3400
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
RVNC
Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨



 


ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On February 24, 2020, Revance Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2019 and the Company's financial outlook for 2020. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this current report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.


ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
Number
  
Description
  
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document)






SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:
February 24, 2020
Revance Therapeutics, Inc.
 
 
 
 
 
 
By:
/s/ Tobin C. Schilke
 
 
 
Tobin C. Schilke
 
 
 
Chief Financial Officer



 EX-99.1 2 rvncq419exhibit991.htm EXHIBIT 99.1 Exhibit

Exhibit 99.1

rvnclogooct2019a01.jpg


Revance Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update

- Conference call and webcast today at 4:30 p.m. ET -

NEWARK, Calif., February 24, 2020 - Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today reported financial results for the fourth quarter and full year ended December 31, 2019, and provided a corporate update.

Key Fourth Quarter 2019 Events and Subsequent Updates

Commercial:

•
BLA for DAXI in Glabellar Lines Accepted by FDA, PDUFA Date Announced. In February, the company received U.S. Food and Drug Administration (FDA) notification that its Biologics License Application (BLA) for DAXI in the treatment of moderate to severe glabellar (frown) lines was accepted for review. Revance has been given a target action date under the Prescription Drug User Fee Act (PDUFA) of November 25, 2020.

•
Signed Exclusive U.S. Distribution Agreement for FDA-Approved TEOXANE Dermal Fillers. In January, Revance entered into a distribution agreement with TEOXANE SA, making Revance the exclusive commercialization partner of the Swiss company’s modern and innovative Resilient Hyaluronic Acid® (RHA®) line of dermal fillers in the U.S., the first and only range of FDA-approved dermal fillers indicated for the correction of dynamic facial wrinkles and folds.

Clinical:

•
Completed Enrollment in Phase 3 Cervical Dystonia Trial and Phase 2 Plantar Fasciitis Trial. In November, Revance announced the completion of enrollment of more than 300 patients in the company’s ASPEN-1 Phase 3 clinical trial for DAXI for the treatment of cervical dystonia. Topline data from this Phase 3 trial is expected in the second half of 2020. In December, Revance enrolled the last of 155 subjects in its Phase 2 placebo-controlled clinical trial of DAXI for the management of plantar fasciitis. The company expects to report topline results from this Phase 2 trial in the second half of 2020.

•
Initiated New Phase 2 Trial for Treatment of the Upper Facial Lines. In December, Revance initiated a new open-label Phase 2 trial of DAXI for treatment of upper facial lines- glabellar (frown), lateral canthal (crow’s feet), and forehead lines combined. This trial is being conducted to assess the safety and efficacy, including potential dosing and injection patterns of DAXI, covering the upper face. The company expects completion of enrollment in the first quarter, with topline results in fourth quarter of 2020.



•
Announced Publication and Presentations of SAKURA Program Results. In December, Revance announced publication in the Journal of the American Academy of Dermatology (JAAD) of the pooled data from two multicenter, randomized, double-blind, placebo-controlled Phase 3 studies (SAKURA 1 and SAKURA 2) evaluating DAXI for the treatment of moderate to severe glabellar lines. In October, Revance published results from the Phase 3 studies, SAKURA 1 and SAKURA 2, in Plastic and Reconstructive Surgery (PRS), the peer reviewed Journal of the American Society of Plastic Surgeons. Also, in October, the company made three oral presentations on DAXI for glabellar lines at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting, in Chicago.

Financial:

•
Closed Public Offering of Common Stock - In January, Revance closed its underwritten public offering of 7,475,000 shares of its common stock at a price to the public of $17.00 per share, which includes the exercise in full by the underwriters of their option to purchase 975,000 shares. The gross proceeds to the company from the offering, before deducting the underwriters’ discounts, commissions and other estimated offering expense payable by Revance, were approximately $127.1 million.

•
Closed Private Offering of Convertible Senior Notes - In February, Revance closed its offering of $287.5 million aggregate principal amount of convertible senior notes due 2027 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Following this financing and the close of the stock offering in January, as of February 14, Revance had $533.3 million in cash, cash equivalents and short-term investments on a preliminary basis.

Corporate:

•
Enhanced Leadership Team. During and subsequent to the end of the fourth quarter, Revance strengthened its executive team through a number of key hires and promotions. These include: the appointment of Mark Foley as President and Chief Executive Officer; the promotion of Dustin Sjuts to Chief Commercial Officer, Aesthetics & Therapeutics; the promotion of Abhay Joshi to Chief Operating Officer and President of R&D and Product Operations; the promotion of Azita Nejad to Senior Vice President, Technical Operations; and the hiring of Dwight Moxie as Senior Vice President, General Counsel & Corporate Secretary.

“With the FDA’s recent acceptance of our BLA submission for DAXI in glabellar lines, and the announcement of our distribution agreement for TEOXANE’s RHA® technology, Revance has constructed an exceptional start to what we believe will be a transformational year for the company. These milestones represent the first two of twelve potential value inflection points for our company in 2020,” said Mark J. Foley, President and Chief Executive Officer of Revance.

“In addition to supporting our DAXI approval efforts, we are focused on preparing for a successful launch of the RHA® line of dermal fillers in the U.S. Also, we have multiple data readouts in the coming months that we believe will reinforce the value of DAXI in both aesthetics and therapeutics, most notably the topline results from our ASPEN-1 Phase 3 trial in cervical dystonia and Phase 2 trial in plantar fasciitis, along with three Phase 2 open-label facial aesthetics studies.”

Mark Foley continued, “We have also capitalized on our company’s recent success with a number of financings that have materially strengthened our balance sheet. This will enable us to execute our strategy and new product launches with confidence. I would like to take this opportunity to thank everyone at Revance for the hard work that has gone into creating the opportunities before us, positioning Revance to become an innovation leader in aesthetics and therapeutics.”



Fourth Quarter and Full Year 2019 Financial Highlights

Cash, cash equivalents and short-term investments as of December 31, 2019 were $290.1 million.

Revenue for the fourth quarter and full year ended December 31, 2019 revenue was $0.1 million and $0.4 million compared to $0.5 million and $3.7 million for the same periods in 2018. The revenue recognized during 2019 represents the portion of revenue earned from the $30 million combined upfront and incremental payments from Mylan under the biosimilar collaboration and license agreement.

Research and development expenses for the fourth quarter and full year ended December 31, 2019 were $27.5 million and $102.9 million compared to $25.5 million and $92.5 million for the same periods in 2018, respectively. The change in research and development expenses is primarily due to the initiation and continuation of clinical trials and studies for multiple therapeutic and aesthetic indications and pre-BLA filing activities for DAXI for the treatment of glabellar lines.

General and administrative expenses for the fourth quarter and full year ended December 31, 2019 were $18.8 million and $62.0 million compared to $13.4 million and $53.9 million for the same periods in 2018, respectively. The increase in general and administrative expenses is primarily due to increased costs related to personnel and infrastructure build-out.

Total operating expenses for the fourth quarter and full year ended December 31, 2019 were $46.3 million and $164.9 million compared to $38.9 million and $146.4 million for the same periods in 2018, respectively. Stock-based compensation for the fourth quarter and full year ended December 31, 2019 was $5.0 million and $17.9 million, respectively. When excluding depreciation and stock-based compensation, total operating expenses for the fourth quarter and full year ended December 31, 2019 were $40.5 million and $144.0 million, respectively.

Net loss for the fourth quarter and full year ended December 31, 2019 was $45.3 million and $159.4 million compared to $40.6 million and $142.6 million for the same periods in 2018, respectively.

Near-Term Milestone Expectations

Aesthetics:
•
Commercial launch of RHA® range of dermal fillers expected in 2Q 2020.
•
Topline results from Phase 2 open-label, dose-escalation study of DAXI in forehead lines expected in 2Q 2020.
•
Topline results from Phase 2 open-label, dose-escalation study of DAXI in lateral canthal lines (crow’s feet) expected in 2Q 2020.
•
Completion of patient enrollment in Phase 2 open-label, dose-escalation study of DAXI in upper facial lines expected in 1Q 2020, with topline results in 4Q 2020.
•
PDUFA date of November 25, 2020, for potential BLA approval of DAXI in glabellar lines.

Therapeutics:
•
Completion of patient enrollment in JUNIPER Phase 2 placebo-controlled, dose-ranging study of DAXI in upper limb spasticity expected in mid-year 2020.
•
Topline results from ASPEN-1 Phase 3 placebo-controlled, parallel-group study of DAXI in cervical dystonia expected in 2H 2020.
•
Topline results from Phase 2 placebo-controlled study of DAXI in plantar fasciitis expected in 2H 2020.

Biosimilar:
•
Decision by Mylan on continuation of biosimilar to BOTOX® program expected by April 30, 2020.



2020 Financial Outlook

Revance expects 2020 U.S. generally accepted accounting principles (“GAAP”) operating expense to be in the range of $270 to $280 million and non-GAAP operating expense, which excludes depreciation and stock-based compensation costs, in the range of $220 to $230 million driven by RHA and DAXI launch activities. With multiple clinical programs underway, along with regulatory and pre-commercial manufacturing activities, Revance anticipates 2020 non-GAAP research and development expense to be $95 to $100 million. With current cash and equivalents, management projects that the company is funded into 2023.

Conference Call

Individuals interested in listening to the conference call may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers and reference conference ID: 2087638; or from the webcast link in the investor relations section of the company’s website at: www.revance.com. A replay of the call will be available beginning February 24, 2020 at 4:30 p.m. PT/7:30 p.m. ET to February 25, 2020 at 4:30 p.m. PT/7:30 p.m. ET. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference conference ID: 2087638. The webcast will be available in the investor relations section on the company's website for 30 days following the completion of the call.

About Revance Therapeutics, Inc.

Revance Therapeutics is a Silicon Valley-based biotechnology company, pioneering new innovations in neuromodulators for aesthetic and therapeutic indications. Revance’s lead product candidate, DaxibotulinumtoxinA for Injection (DAXI), combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DAXI in glabellar (frown) lines and is pursuing U.S. regulatory approval in 2020. Revance is also evaluating DAXI in the upper face, including glabellar lines, forehead lines and crow’s feet, as well as in three therapeutic indications - cervical dystonia, adult upper limb spasticity and plantar fasciitis. Beyond DAXI, Revance gained exclusive rights to commercialize TEOXANE SA’s Resilient Hyaluronic Acid® (RHA®) line of fillers in the U.S., the first and only range of FDA-approved dermal fillers for correction of dynamic facial wrinkles and folds. Revance has also begun development of a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.

“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.
BOTOX® is a registered trademark of Allergan, Inc.



Forward-Looking Statements

This press release contains forward-looking statements, including statements related to Revance Therapeutics' 2020 financial outlook, milestone expectations, expected cash runway and other financial performance; the process and timing of, and ability to complete, current and anticipated future clinical development of our investigational drug product candidates; the initiation, design, enrollment, submission, timing and results of our clinical studies, including the near-term milestone expectations described above; development of a biosimilar to BOTOX®; results of our non-clinical programs; statements about our business strategy, timeline and other goals and market for our anticipated products, plans and prospects, including our pre-commercialization plans; statements about our ability to obtain, and the timing relating to, regulatory approval with respect to our drug product candidates and to launch products, including with respect to the anticipated approval of DAXI and expected PDUFA date; potential benefits of our drug product candidates and our technologies, including with respect to the RHA line of dermal fillers.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates, including our ability to receive timely approval of DAXI; our ability to obtain funding for our operations; our plans to research, develop, and commercialize our drug product candidates; our ability to achieve market acceptance of our drug product candidates; unanticipated costs or delays in research, development, and commercialization efforts; the applicability of clinical study results to actual outcomes; the size and growth potential of the markets for our drug product candidates; our ability to successfully commercialize our drug product candidates and the timing of commercialization activities; the rate and degree of market acceptance of our drug product candidates; our ability to develop sales and marketing capabilities; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Revance's periodic filings with the Securities and Exchange Commission (the "SEC"), including factors described in the section entitled "Risk Factors" in Exhibit 99.2 of our current report on Form 8-K filed February 10, 2020. These forward-looking statements speak only as of the date hereof. Revance disclaims any obligation to update these forward-looking statements.

Use of Non-GAAP Financial Measures

Revance has presented certain non-GAAP financial measures in this release. This release and the reconciliation tables included herein include total non-GAAP operating expense and non-GAAP R&D expense, both of which exclude depreciation, stock-based compensation, and non-recurring milestone costs. Revance excludes depreciation, stock-based compensation, and non-recurring milestone costs because management believes the exclusion of these items is helpful to investors to evaluate Revance's recurring operational performance. Revance management uses these non-GAAP financial measures to monitor and evaluate its operating results and trends on an on-going basis, and internally for operating, budgeting and financial planning purposes. The non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP but should not be considered a substitute for or superior to GAAP results.
###


Contacts
INVESTORS
Revance Therapeutics, Inc.:
Jeanie Herbert, 714-325-3584
jherbert@revance.com
or
Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620
laurence@gilmartinir.com

MEDIA
Revance Therapeutics, Inc.:
Sara Fahy, 949-887-4476
sfahy@revance.com
or
General Media:
Y&R:
Jenifer Slaw, 347-971-0906
jenifer.slaw@YR.com
or
Trade Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com

Source: Revance Therapeutics, Inc.




REVANCE THERAPEUTICS, INC.
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
(Unaudited)
 
As of December 31,
 
2019
 
2018
ASSETS
CURRENT ASSETS
 
 
 
Cash and cash equivalents
$
171,160

 
$
73,256

Short-term investments
118,955

 
102,556

Accounts and other receivables
—

 
27,000

Prepaid expenses and other current assets
6,487

 
5,110

Total current assets
296,602

 
207,922

Property and equipment, net
14,755

 
14,449

Operating lease right of use assets
26,531

 
—

Restricted cash
730

 
730

Other non-current assets
1,669

 
3,247

TOTAL ASSETS
$
340,287

 
$
226,348

LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
 
 
 
Accounts payable
$
8,010

 
$
8,434

Accruals and other current liabilities
18,636

 
14,948

Deferred revenue, current portion
7,911

 
8,588

Operating lease liabilities, current portion
3,470

 
—

Derivative liability, current
2,952

 
—

Total current liabilities
40,979

 
31,970

Deferred revenue, net of current portion
47,948

 
42,684

Operating lease liabilities, net of current portion
25,870

 
—

Deferred rent
—

 
3,319

Derivative liability, non-current
—

 
2,753

TOTAL LIABILITIES
114,797

 
80,726

STOCKHOLDERS’ EQUITY
 
 
 
Convertible preferred stock, par value $0.001 per share — 5,000,000 shares authorized, and no shares issued and outstanding as of December 31, 2019 and 2018
—

 
—

Common stock, par value $0.001 per share — 95,000,000 shares authorized both as of December 31, 2019 and 2018; 52,374,735 and 36,975,203 shares issued and outstanding as of December 31, 2019 and 2018, respectively
52

 
37

Additional paid-in capital
1,069,639

 
830,368

Accumulated other comprehensive income (loss)
3

 
(8
)
Accumulated deficit
(844,204
)
 
(684,775
)
TOTAL STOCKHOLDERS’ EQUITY
225,490

 
145,622

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
$
340,287

 
$
226,348






REVANCE THERAPEUTICS, INC.
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(Unaudited)
 
Quarter Ended December 31,
 
Year Ended December 31,
 
2019
 
2018
 
2019
 
2018
Revenue
$
89

 
$
487

 
$
413

 
$
3,729

Operating expenses:
 
 
 
 
 
 
 
Research and development
27,493

 
25,532

 
102,861

 
92,500

General and administrative
18,766

 
13,358

 
62,011

 
53,863

Total operating expenses
46,259

 
38,890

 
164,872

 
146,363

Loss from operations
(46,170
)
 
(38,403
)
 
(164,459
)
 
(142,634
)
Interest income
1,037

 
924

 
5,532

 
4,023

Interest expense
—

 
—

 
—

 
(44
)
Changes in fair value of derivative liability
(60
)
 
10

 
(199
)
 
(140
)
Other expense, net
(133
)
 
(147
)
 
(303
)
 
(773
)
Loss before income taxes
(45,326
)
 
(37,616
)
 
(159,429
)
 
(139,568
)
Income tax provision
—

 
(3,000
)
 
—

 
(3,000
)
Net loss
(45,326
)
 
(40,616
)
 
(159,429
)
 
(142,568
)
Unrealized gain (loss) and adjustment on securities included in net loss
(39
)
 
125

 
11

 
(8
)
Comprehensive loss
$
(45,365
)
 
$
(40,491
)
 
$
(159,418
)
 
$
(142,576
)
Basic and diluted net loss
$
(45,326
)
 
$
(40,616
)
 
$
(159,429
)
 
$
(142,568
)
Basic and diluted net loss per share
$
(0.99
)
 
$
(1.12
)
 
$
(3.67
)
 
$
(3.94
)
Basic and diluted weighted-average number of shares used in computing net loss per share
45,626,470

 
36,334,364

 
43,460,804

 
36,171,582






REVANCE THERAPEUTICS, INC.
Reconciliation of GAAP Operating Expense to Non-GAAP Operating Expense
(In thousands)
(Unaudited)

 
Quarter Ended December 31, 2019
 
Year Ended December 31, 2019
Operating expense:
 
 
 
GAAP operating expense
$
46,259

 
$
164,872

Adjustments:
 
 
 
Stock-based compensation
(5,040
)
 
(17,922
)
Depreciation
(757
)
 
(2,909
)
Non-GAAP operating expense
$
40,462

 
$
144,041



REVANCE THERAPEUTICS, INC.
Reconciliation of GAAP R&D Expense to Non-GAAP R&D Expense
(In thousands)
(Unaudited)

 
Quarter Ended December 31, 2019
 
Year Ended December 31, 2019
R&D expense:
 
 
 
GAAP R&D expense
$
27,493

 
$
102,861

Adjustments:
 
 
 
Stock-based compensation
(2,074
)
 
(8,512
)
Depreciation
(514
)
 
(2,039
)
Non-GAAP R&D expense
$
24,905

 
$
92,310




 EX-101.SCH 3 rvnc-20200224.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Cover Page Document link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 rvnc-20200224_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 rvnc-20200224_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 rvnc-20200224_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover page. Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag EX-101.PRE 7 rvnc-20200224_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 rvnclogooct2019a01.jpg begin 644 rvnclogooct2019a01.jpg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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover Page Document
Feb. 24, 2020
Cover page.  
Entity Central Index Key 0001479290
Document Type 8-K
Document Period End Date Feb. 24, 2020
Entity Registrant Name Revance Therapeutics, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36297
Entity Tax Identification Number 77-0551645
Entity Address, Address Line One 7555 Gateway Boulevard
Entity Address, City or Town Newark
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94560
City Area Code 510
Local Phone Number 742-3400
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol RVNC
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
ZIP 11 0001479290-20-000038-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001479290-20-000038-xbrl.zip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end EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 95 1 false 0 0 false 0 false false R1.htm 0001000 - Document - Cover Page Document Sheet http://www.revance.com/role/CoverPageDocument Cover Page Document Cover 1 false false All Reports Book All Reports rvncq419er8-k.htm rvnc-20200224.xsd rvnc-20200224_cal.xml rvnc-20200224_def.xml rvnc-20200224_lab.xml rvnc-20200224_pre.xml rvncq419exhibit991.htm http://xbrl.sec.gov/dei/2019-01-31 true true XML 15 rvncq419er8-k_htm.xml IDEA: XBRL DOCUMENT 0001479290 2020-02-24 2020-02-24 false 0001479290 8-K 2020-02-24 Revance Therapeutics, Inc. DE 001-36297 77-0551645 7555 Gateway Boulevard Newark CA 94560 510 742-3400 false false false false Common Stock, par value $0.001 per share RVNC NASDAQ false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rvncq419er8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "rvnc-20200224_cal.xml" ] }, "definitionLink": { "local": [ "rvnc-20200224_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "rvncq419er8-k.htm" ] }, "labelLink": { "local": [ "rvnc-20200224_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "rvnc-20200224_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "rvnc-20200224.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rvnc", "nsuri": "http://www.revance.com/20200224", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq419er8-k.htm", "contextRef": "D2020Q1February24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page Document", "role": "http://www.revance.com/role/CoverPageDocument", "shortName": "Cover Page Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq419er8-k.htm", "contextRef": "D2020Q1February24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 17 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; }